NO993646D0 - Thiazole benzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity - Google Patents
Thiazole benzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesityInfo
- Publication number
- NO993646D0 NO993646D0 NO993646A NO993646A NO993646D0 NO 993646 D0 NO993646 D0 NO 993646D0 NO 993646 A NO993646 A NO 993646A NO 993646 A NO993646 A NO 993646A NO 993646 D0 NO993646 D0 NO 993646D0
- Authority
- NO
- Norway
- Prior art keywords
- obesity
- agonists
- diabetes
- beta
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3676097P | 1997-01-28 | 1997-01-28 | |
| GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
| PCT/US1998/001317 WO1998032753A1 (en) | 1997-01-28 | 1998-01-23 | THIAZOLE BENZENESULFONAMIDES AS β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO993646D0 true NO993646D0 (en) | 1999-07-27 |
| NO993646L NO993646L (en) | 1999-09-27 |
Family
ID=26311166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO993646A NO993646L (en) | 1997-01-28 | 1999-07-27 | Thiazolebenzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0968209A1 (en) |
| JP (1) | JP2001509166A (en) |
| KR (1) | KR20000070568A (en) |
| CN (1) | CN1251099A (en) |
| AR (1) | AR011092A1 (en) |
| AU (1) | AU728812B2 (en) |
| BG (1) | BG103686A (en) |
| BR (1) | BR9807096A (en) |
| CA (1) | CA2278739A1 (en) |
| EA (1) | EA199900692A1 (en) |
| EE (1) | EE9900328A (en) |
| HR (1) | HRP980044A2 (en) |
| HU (1) | HUP0002053A3 (en) |
| ID (1) | ID22273A (en) |
| IL (1) | IL131130A0 (en) |
| IS (1) | IS5131A (en) |
| NO (1) | NO993646L (en) |
| PE (1) | PE52299A1 (en) |
| PL (1) | PL334833A1 (en) |
| SK (1) | SK100099A3 (en) |
| TR (1) | TR199902442T2 (en) |
| WO (1) | WO1998032753A1 (en) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19824175A1 (en) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino azole compounds |
| ES2436610T3 (en) | 2000-01-21 | 2014-01-03 | Novartis Ag | Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| AU2710301A (en) * | 2000-01-28 | 2001-08-07 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
| TR200401359T4 (en) | 2000-03-31 | 2004-08-23 | Pfizer Products Inc. | Process for the preparation of substituted pyridines |
| SK632003A3 (en) | 2000-07-13 | 2003-06-03 | Lilly Co Eli | Beta3 adrenergic agonists |
| US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
| US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
| US6498170B2 (en) * | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
| US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
| AU2002234134A1 (en) | 2000-11-10 | 2002-05-21 | Eli Lilly And Company | 3-substituted oxindole beta 3 agonists |
| EP1348706B1 (en) | 2000-12-08 | 2009-08-19 | Takeda Pharmaceutical Company Limited | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
| AR035605A1 (en) | 2000-12-11 | 2004-06-16 | Bayer Corp | DERIVATIVES OF AMINOMETIL CHROMANO DI-SUBSTITUTES, A METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3-ADRENE-RECEPTORS AGONISTS |
| AR035858A1 (en) | 2001-04-23 | 2004-07-21 | Bayer Corp | CHROME DERIVATIVES 2,6-SUBSTITUTES, PHARMACEUTICAL COMPOSITIONS, USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF USEFUL MEDICINES AS BETA-3 ADRENORRECEPTING AGONISTS |
| ES2255621T3 (en) * | 2001-06-22 | 2006-07-01 | MERCK & CO., INC. | THYROSINE KINASE INHIBITORS. |
| WO2003016276A2 (en) | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | 3-substituted oxindole beta-3 agonists |
| WO2003016307A1 (en) | 2001-08-14 | 2003-02-27 | Eli Lilly And Company | β3 ADRENERGIC AGONISTS |
| ES2256560T3 (en) * | 2001-10-12 | 2006-07-16 | Bayer Pharmaceuticals Corporation | HETEROCICLOS OF 5 MEMBERS CONTAINING NITROGEN SUBSTITUTED WITH FELINE FOR THE TREATMENT OF OBESITY. |
| WO2003044016A1 (en) | 2001-11-20 | 2003-05-30 | Eli Lilly And Company | 3-SUBSTITUTED OXINDOLE β3 AGONISTS |
| ES2299618T3 (en) | 2001-11-20 | 2008-06-01 | Eli Lilly And Company | BETA-3-ADRENERGIC AGONISTS. |
| US7009060B2 (en) | 2002-01-11 | 2006-03-07 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists |
| US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
| WO2006132196A1 (en) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | NOVEL PHARMACEUTICAL COMPRISING β3 AGONIST |
| CN102940638B (en) | 2005-09-14 | 2015-03-04 | 武田药品工业株式会社 | Dipeptidyl peptidase inhibitors for treating diabetic |
| CA2624030A1 (en) | 2005-09-29 | 2007-04-12 | Tianying Jian | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| AU2006302562A1 (en) | 2005-10-04 | 2007-04-19 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment of urinary frequency, urinary urgency and urinary incontinence |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
| MX2009013293A (en) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| ES2627848T3 (en) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP2011528375A (en) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CN102271509A (en) | 2008-10-31 | 2011-12-07 | 默沙东公司 | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| PL2531501T3 (en) | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Apoptosis signal-regulating kinase 1 inhibitors |
| JP2013520502A (en) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | Novel cyclic benzimidazole derivatives that are useful anti-diabetic drugs |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| MA34916B1 (en) | 2011-02-25 | 2014-02-01 | Merck Sharp & Dohme | NOVEL CYCLIC AZABENZIMIDAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AGENTS |
| CA2880901A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| ES2394349B1 (en) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Use of selective beta-3 adrenergic receptor agonists for the treatment of pulmonary hypertension |
| US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
| RU2015140066A (en) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | ANTI-DIABETIC BICYCLIC COMPOUNDS |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| JP2016514671A (en) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | Guanylate cyclase agonists and uses thereof |
| KR102272746B1 (en) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298A4 (en) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0091749A3 (en) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them |
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 PL PL98334833A patent/PL334833A1/en unknown
- 1998-01-23 CN CN98803585A patent/CN1251099A/en active Pending
- 1998-01-23 JP JP53214898A patent/JP2001509166A/en active Pending
- 1998-01-23 IL IL13113098A patent/IL131130A0/en unknown
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/en not_active Application Discontinuation
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/en not_active Application Discontinuation
- 1998-01-23 EA EA199900692A patent/EA199900692A1/en unknown
- 1998-01-23 EP EP98903677A patent/EP0968209A1/en not_active Withdrawn
- 1998-01-23 ID IDW990755A patent/ID22273A/en unknown
- 1998-01-23 SK SK1000-99A patent/SK100099A3/en unknown
- 1998-01-23 EE EEP199900328A patent/EE9900328A/en unknown
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/en not_active IP Right Cessation
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/en unknown
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/en unknown
- 1998-01-23 CA CA002278739A patent/CA2278739A1/en not_active Abandoned
- 1998-01-27 AR ARP980100357A patent/AR011092A1/en unknown
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/en not_active Application Discontinuation
- 1998-01-28 PE PE1998000064A patent/PE52299A1/en not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/en unknown
- 1999-07-27 NO NO993646A patent/NO993646L/en not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ID22273A (en) | 1999-09-23 |
| IS5131A (en) | 1999-07-23 |
| HUP0002053A3 (en) | 2001-09-28 |
| BR9807096A (en) | 2000-04-18 |
| AR011092A1 (en) | 2000-08-02 |
| PL334833A1 (en) | 2000-03-27 |
| EA199900692A1 (en) | 2000-02-28 |
| EP0968209A1 (en) | 2000-01-05 |
| AU6038498A (en) | 1998-08-18 |
| AU728812B2 (en) | 2001-01-18 |
| EE9900328A (en) | 2000-02-15 |
| SK100099A3 (en) | 2000-05-16 |
| KR20000070568A (en) | 2000-11-25 |
| PE52299A1 (en) | 1999-05-26 |
| NO993646L (en) | 1999-09-27 |
| TR199902442T2 (en) | 2000-07-21 |
| JP2001509166A (en) | 2001-07-10 |
| IL131130A0 (en) | 2001-01-28 |
| HUP0002053A2 (en) | 2001-08-28 |
| BG103686A (en) | 2000-06-30 |
| WO1998032753A1 (en) | 1998-07-30 |
| CN1251099A (en) | 2000-04-19 |
| HRP980044A2 (en) | 1998-10-31 |
| CA2278739A1 (en) | 1998-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO993646D0 (en) | Thiazole benzenesulfonamides as <beta> 3 agonists for the treatment of diabetes and obesity | |
| NO964548D0 (en) | Substituted sulfonamides as selective 3 agonists for the treatment of diabetes and obesity | |
| EP0906310A4 (en) | OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE -g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | |
| NO20006630D0 (en) | Pharmaceutical composition for the treatment of diabetes | |
| AU3723297A (en) | Substituted sulfonamides as selective beta3 agonists for the treatment of diabetes and obesity | |
| GB9619331D0 (en) | Selective ›3 agonists for the treatment of diabetes and obesity | |
| DZ2936A1 (en) | New modified release composition for the treatment of diabetes. | |
| NO976063D0 (en) | Procedure for the treatment of diabetes | |
| FI953180A0 (en) | Compositions for the treatment of diabetic complications | |
| DK1206457T3 (en) | Biaryl-oxa (thia) zole derivatives and their use as modulators PPAPs | |
| NO961432D0 (en) | Benzophiophenes and related compounds as estrogen agonists | |
| DK0996444T3 (en) | Treatment of diabetes with thiazolidinedione and metformin | |
| ZA953336B (en) | Substituted sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | |
| NO20001914D0 (en) | <alfa> -Aryl-N-alkylnitrons and pharmaceutical compositions containing them | |
| NO972451D0 (en) | 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and preparations and process for use thereof | |
| NO307049B1 (en) | Compound which are <Beta> -adrenergic agonists, their use and pharmaceutical composition | |
| NO20022087D0 (en) | Procedure for the treatment of diabetes | |
| ZA98647B (en) | Thiazole benzenesulfonamides as beta3 agonists for the treatment of diabetes and obesity | |
| DE69432116T2 (en) | Ceramic composition and thermistor containing this ceramic composition | |
| ITPR970019A0 (en) | PROCEDURE AND APPARATUS FOR THE EXTERNAL INSPECTION OF CONTAINERS. | |
| DE69610602T2 (en) | Antiferroelectric liquid crystal compound and antiferroelectric liquid crystal composition | |
| NO996264L (en) | Treatment of diabetes with thiazolidinedione and sulfonylurea | |
| NO20000229D0 (en) | Treatment of diabetes with thiazolidinedione and sulfonylurea | |
| BR9912125B1 (en) | BENZENOSULPHONYLURIAS AND - 2,5-SUBSTITUTED THIOURERIA, PROCESSES FOR PREPARING THERE, APPLICATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME | |
| NO996467D0 (en) | Process for the preparation of thiazofurine and other C-nucleosides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |